TY - JOUR
T1 - Formation of assemblies on cell membranes by secreted proteins: molecular studies of free lambda light chain aggregates found on the surface of myeloma cells
AU - Hutchinson, Andrew T
AU - Malik, Ansha
AU - Berkahn, Mark B
AU - Agostino, Mark James
AU - To, Joyce
AU - Tacchi, Jessica L
AU - Djordjevic, Steven P
AU - Turnbull, Lynne
AU - Whitchurch, Cynthia Beth
AU - Edmundson, A B
AU - Jones, Darren R
AU - Raison, Robert L
AU - Ramsland, Paul Allen
PY - 2013
Y1 - 2013
N2 - We have described the presence of cell-membrane-associated kFLCs (free immunoglobulin light chains) on the surface of myeloma cells. Notably, the anti-?FLC mAb (monoclonal antibody) MDX-1097 is being assessed in clinical trials as a therapy for ? light chain isotype multiple myeloma. Despite the clinical potential of anti-FLC mAbs, there have been limited studies on characterizing membrane-associated FLCs at a molecular level. Furthermore, it is not known whether ?FLCs can associate with cell membranes of myeloma cells. In the present paper, we describe the presence of ?FLCs on the surface of myeloma cells. We found that cell-surface-associated ?FLCs are bound directly to the membrane and in an aggregated form. Subsequently, membrane interaction studies revealed that ?FLCs interact with saturated zwitterionic lipids such as phosphatidylcholine and phosphatidylethanolamine, and using automated docking, we characterize a potential recognition site for these lipids. Atomic force microscopy confirmed that membrane-associated ?FLCs are aggregated. Given the present findings, we propose a model whereby individual FLCs show modest affinity for zwitterionic lipids, with aggregation stabilizing the interaction due to multivalency. Notably, this is the first study to image FLCs bound to phospholipids and provides important insights into the possible mechanisms of membrane association by this unique myeloma surface antigen. ? 2013 Biochemical Society.
AB - We have described the presence of cell-membrane-associated kFLCs (free immunoglobulin light chains) on the surface of myeloma cells. Notably, the anti-?FLC mAb (monoclonal antibody) MDX-1097 is being assessed in clinical trials as a therapy for ? light chain isotype multiple myeloma. Despite the clinical potential of anti-FLC mAbs, there have been limited studies on characterizing membrane-associated FLCs at a molecular level. Furthermore, it is not known whether ?FLCs can associate with cell membranes of myeloma cells. In the present paper, we describe the presence of ?FLCs on the surface of myeloma cells. We found that cell-surface-associated ?FLCs are bound directly to the membrane and in an aggregated form. Subsequently, membrane interaction studies revealed that ?FLCs interact with saturated zwitterionic lipids such as phosphatidylcholine and phosphatidylethanolamine, and using automated docking, we characterize a potential recognition site for these lipids. Atomic force microscopy confirmed that membrane-associated ?FLCs are aggregated. Given the present findings, we propose a model whereby individual FLCs show modest affinity for zwitterionic lipids, with aggregation stabilizing the interaction due to multivalency. Notably, this is the first study to image FLCs bound to phospholipids and provides important insights into the possible mechanisms of membrane association by this unique myeloma surface antigen. ? 2013 Biochemical Society.
UR - http://www.ncbi.nlm.nih.gov/pubmed/23822104
U2 - 10.1042/BJ20130575
DO - 10.1042/BJ20130575
M3 - Article
SN - 0264-6021
VL - 454
SP - 479
EP - 489
JO - Biochemical Journal
JF - Biochemical Journal
IS - 3
ER -